New drug candidate EP395 tested in temporary lung inflammation model
NCT ID NCT06677918
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested an experimental drug called EP395 in 40 healthy adults. Researchers used a safe, temporary lung inflammation challenge to see how EP395 affects immune markers in the blood and lungs. The main goal was to gather safety data and understand the drug's effects, not to treat a disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Division of Clinical Airway Research
Hanover, 30625, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?